BUYINS.NET Updates Provectus Pharmaceuticals SqueezeTrigger Report

Before you go, we thought you'd like these...
Before you go close icon

BUYINS.NET Updates Provectus Pharmaceuticals SqueezeTrigger Report

  • Approximately 68.8 Million Shares Shorted Since August 2009
  • Short Squeeze Has Begun As Stock Above $0.93 SqueezeTrigger Price

KNOXVILLE, Tenn.--(BUSINESS WIRE)-- Provectus Pharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company reports that BUYINS.NET (http://www.buyins.net), a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has issued the following update of its coverage on the Company after releasing the latest short sale data through September 19, 2013.


The total aggregate number of shares shorted since August 2009 is approximately 68.8 million shares. Approximately 32.44% of daily trading volume is short selling. The SqueezeTrigger price for all PVCT shares shorted is $0.93. A short squeeze has just begun as PVCT is above the $0.93 SqueezeTrigger Price.

Click for Original Report: http://www.buyins.com/reports/pvct9-20-13.pdf

Click for Updated SqueezeTrigger: http://www.buyins.com/images2/pvctstr9-20-13.jpg

Click for Updated Friction Factor: http://www.buyins.com/images2/pvctff9-20-13.jpg

Click here for detailed explanation: http://www.buyins.com/brochure.pdf

Friction Factor calculates if a fair market is being made in the shares of PVCT. 59% of the previous 37 trading days have been positive or bullish-biased and 41% have been negative or bearish-biased.

Regulation SHO requires bona-fide market-making activities to include making purchases and sales in roughly comparable amounts. The Commission has stated that bona-fide market-making DOES NOT include activity that is related to speculative selling strategies or investment purposes of the broker-dealer and is disproportionate to the usual market making patterns or practices of the broker-dealer in that security. Likewise, where a market-maker posts continually at or near the best offer, but does not also post at or near the best bid, the market-maker's activities would not generally qualify as bona-fide market-making. Moreover, a market-maker that continually executes short sales away from its posted quotes would generally not be considered to be engaging in bona-fide market-making.

BUYINS.NET monitors PVCT market-makers daily for compliance with Fair Market-Making Requirements.

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies and comparable valuations.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has been paid $1,116 per month for data provided in twelve monthly reports. PVCT has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.



BUYINS.NET
Thomas Ronk
800-715-9999
tom@buyins.net
http://www.buyins.net

KEYWORDS:   United States  North America  Tennessee

INDUSTRY KEYWORDS:

The article BUYINS.NET Updates Provectus Pharmaceuticals SqueezeTrigger Report originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners